Clinical trials
CIDP clinical trials
Below are recruiting cidp clinical trials, each written for real people, not researchers. We’re tracking 29 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06920004RecruitingPhase 3
Testing empasiprubart vs IVIg for chronic CIDP
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
Birmingham, AlabamaAges 18 years+ - NCT07264426Recruiting
Real-world study of efgartigimod for CIDP
This study looks at how well efgartigimod works in everyday use for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to understand the real-world benefits of this treatment.
Wilmington, North CarolinaAges 18 years+ - NCT07091630RecruitingPhase 3
A study of empasiprubart for chronic inflammatory demyelinating polyneuropathy (CIDP)
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
Birmingham, AlabamaAges 18 years+ - NCT03684018RecruitingPhase 4
Testing two doses of Privigen for children with CIDP
This study tests whether two different dose levels of Privigen (a type of immune blood treatment) are safe and effective for children and teens with CIDP. It may help improve nerve-related symptoms in people whose CIDP has been confirmed or is being evaluated as likely.
Phoenix, ArizonaAges 2–17 - NCT04589299RecruitingPhase 4
Subcutaneous immune globulin for newly diagnosed CIDP
This study tests whether giving immune globulin under the skin (SCIG) can help people with newly diagnosed CIDP. It may help improve muscle strength and nerve symptoms while avoiding the need for earlier IVIG/SCIG treatment.
AalborgAges 18 years+ - NCT04881682RecruitingPhase 2
Testing blood-cleansing vs immunoglobulin for CIDP
This Phase 2 study compares a blood-cleansing treatment (immunoadsorption) with standard immune-boosting treatment (intravenous immunoglobulins) for chronic inflammatory demyelinating polyneuropathy (CIDP). It may help people whose steroid treatment did not work well, or who cannot take steroids.
Ulm, Baden-WurttembergAges 18 years+ - NCT05584631RecruitingPhase 1
Switching IVIG to weekly SCIG for CIDP treatment
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
New Brunswick, New JerseyAges 18–65 - NCT06538064Recruiting
Study of HyQvia for Adults with CIDP in Routine Care
This study looks at how well HyQvia works for adults with CIDP in everyday medical practice. It includes people who are already using HyQvia or are switching to it.
Rancho Mirage, CaliforniaAges 18 years+ - NCT06747351RecruitingPhase 3
Comparing two immune globulin treatments for CIDP
This study tests if TAK-881 is as safe and effective as HYQVIA for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). You may join if you have been stable on immune globulin therapy and have certain disability levels.
Scottsdale, ArizonaAges 18 years+ - NCT06798012RecruitingPhase 2
TAK-411 for adults with CIDP
This study tests a new investigational drug called TAK-411 for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for people who have already responded to immunoglobulin therapy and are on a stable dose.
La Jolla, CaliforniaAges 18 years+ - NCT07273903Recruiting
Tracking CIDP treatment with a smartwatch
This trial tests whether a smartwatch can help monitor how well subcutaneous immunoglobulin (fSCIG) works for people with CIDP who recently switched from IVIG or plan to switch. It aims to make treatment tracking easier and more convenient.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT07461896Recruiting
Nerve function study in Charcot-Marie-Tooth and related neuropathies
This study looks at how nerves work and their structure in people with Charcot-Marie-Tooth disease, CIDP, or anti-MAG neuropathy. It may help doctors better understand these conditions.
MilanAges 18 years+ - NCT05327114RecruitingPhase 2/Phase 3
Nipocalimab for adults with chronic inflammatory CIDP nerve disease
This trial tests nipocalimab (an antibody medicine) to improve symptoms and control activity in chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. It may help reduce disease activity and disability, while checking safety.
Centennial, ColoradoAges 18 years+ - NCT06290141RecruitingPhase 3
Testing riliprubart vs. standard IVIg for CIDP
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
Homewood, AlabamaAges 18 years+ - NCT06752356RecruitingPhase 3
A study of a new IVIG treatment for CIDP
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
Tampa, FloridaAges 18 years+ - NCT04929236RecruitingPhase 3
Testing different PANZYGA doses for children with CIDP
This Phase 3 study compares different dose schedules of PANZYGA (immune-globulin) in children with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). It aims to find a dosing plan that is both safe and effective for improving symptoms and function.
Birmingham, AlabamaAges 2–17 - NCT07032662RecruitingPhase 2
Testing Imeroprubart for adults with CIDP
This trial tests a new drug called Imeroprubart for people with CIDP who are already on a stable treatment like steroids or immunoglobulin. The goal is to see if the drug can help control symptoms better.
Tucson, ArizonaAges 18 years+ - NCT06859099Enrolling by invitationPhase 3
Long-term safety study of Riliprubart for CIDP
This study checks the long-term safety and how well riliprubart works for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for those who have already taken riliprubart in a previous study.
Homewood, AlabamaAges 18 years+ - NCT05004493Recruiting
Plasma exchange patient registry and sample collection
This study collects information and blood or other samples from people who are getting plasma exchange therapy. The goal is to build a registry (a organized database) that researchers can use to better understand and improve care.
Iowa City, IowaAges 12–99 - NCT06040567Recruiting
Polyneuropathy, Impairments and Physical Activity Study
This study looks at how polyneuropathy (nerve damage) affects your daily physical activity and overall function. It aims to understand the link between nerve damage and movement, which could help improve care.
CopenhagenAges 18–100 - NCT06183645Recruiting
Predicting CIDP decline during IVIg treatment changes
This study looks at people with CIDP who are stable on IVIg treatment to see if we can predict when they might get worse if their treatment is adjusted. It aims to make treatment management easier and more personalized.
Liège, LiègeAges 18–99 - NCT06299748Recruiting
Efgartigimod safety study for pregnancy and breastfeeding
This study is for women who have taken efgartigimod (a medicine for certain autoimmune conditions) right before or during pregnancy, or while breastfeeding. Researchers will monitor moms, fetuses, and babies to check for side effects and ensure safety.
Morgantown, West VirginiaAges Any age - NCT07540221RecruitingPhase 3
Comparing two immune therapy infusions for nerve damage
This study tests whether a new immune therapy called XEMBIFY works as well as a standard treatment (Gamunex-C) for CIDP, a condition where the immune system damages nerves and causes weakness. Both are given as infusions under the skin every three weeks.
Rancho Mirage, CaliforniaAges 18 years+ - NCT06615622Recruiting
Using ultrasound to detect nerve changes in GBS and CIDP
This study tests if ultrasound can find nerve problems in people with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP), and if it helps doctors diagnose and predict outcomes early.
AsyutAges 18–75
Hear when a new CIDP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cidp?
- Yes. Clin2 currently lists 29 recruiting cidp studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cidp trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cidp trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.